| Literature DB >> 33328405 |
Sayaka Sato1, Saki Fushimi1, Yuta Tahata1, Hiroya Mizutamari1, Nobuya Mimori1, Yuhei Kato1, Yohei Horikawa1.
Abstract
Objective In an effort to reduce mortality from gastric cancer, endoscopic screening was introduced in 2016 as a nationwide screening program in Japan. Recent developments in high-definition endoscopic imaging and diagnostic strategies have enabled the simultaneous detection of other upper gastrointestinal (U-GI) malignancies. Therefore, we conducted a study to evaluate the feasibility of endoscopic screening for U-GI malignancy in a comprehensive health checkup. Methods We retrospectively reviewed the data of 13,120 participants who had received a comprehensive health checkup in a single institution between April 2012 and March 2018. Participants were divided into two groups [gastrointestinal endoscopy (GIE) group (n=9,142) and gastrointestinal X-ray (X-ray) group (n=3,978)] and compared with regards to the screening results, adverse events, and detection rate of U-GI malignancies (gastric cancer or other) using a propensity-score matched analysis. Results The gastric cancer detection rate was significantly higher in the GIE group [34/9,142 (0.48%)] than in the X-ray group [3/3,978 (0.08%)] (p=0.003). Other U-GI malignancies were found only in the GIE group and comprised two hypopharyngeal cancers, five esophageal cancers, two duodenal cancers, and one duodenal gastrointestinal stromal tumor. Adverse events occurred in 6/9,142 (0.07%) participants in the GIE group and 18/3,978 (0.45%) participants in the X-ray group (p<0.0001). A propensity-score matched analysis yielded 1,551 matched pairs, and the detection rate of gastric cancer and other U-GI malignancies remained significantly higher in the GIE group than in the X-ray group. Conclusion This study indicated that not only gastric cancer but also other U-GI malignancies can be detected by endoscopic screening.Entities:
Keywords: endoscopy; screening and diagnosis; upper gastrointestinal malignancies
Mesh:
Year: 2020 PMID: 33328405 PMCID: PMC8188019 DOI: 10.2169/internalmedicine.6020-20
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Figure.Proportion of each screening method used in comprehensive health checkups at Hiraka General Hospital between April 2012 and March 2018. The number on the bar indicates the participant count and proportion of each screening method.
Baseline Characteristics of 13,120 Participants That Underwent a Comprehensive Health Checkup.
| GIE group | X-ray group | p | AS | |
|---|---|---|---|---|
| Age, median [range] (y) | 57 [24-94] | 53 [21-86] | <0.001* | 0.580 |
| Sex | ||||
| Male, n (%) | 5,737 (62.8) | 1,641 (41.3) | <0.001† | 0.441 |
| Cigarette smoking | 1,642 (18.0) | 718 (18.0) | 0.920† | 0.002 |
| positive, n (%) | ||||
| Alcohol consumption | 5,651 (61.8) | 2,184 (54.9) | <0.001† | 0.143 |
| positive, n (%) | ||||
| BMI, mean [SD] (kg/m2) | 23.7 [3.6] | 23.1 [3.6] | <0.001* | 0.163 |
BMI: body mass index, SD: standerd deviation, *: student's t-test, †: Chi-square test, ASD: Absolute standerdized difference
Baseline Characteristics after Propensity-score Matched Analysis.
| GIE group | X-ray group | p | ASD | |
|---|---|---|---|---|
| Age, median [range] (y) | 52 [24-83] | 53 [21-86] | 0.202* | 0.046 |
| Sex | ||||
| Male, n (%) | 742 (47.8) | 739 (47.7) | 0.914† | 0.004 |
| Cigarette smoking | 304 (19.6) | 298 (19.2) | 0.785† | 0.010 |
| positive, n (%) | ||||
| Alcohol consumption | 865 (55.8) | 881 (56.8) | 0.563† | 0.021 |
| positive, n (%) | ||||
| BMI, mean [SD] (kg/m2) | 23.5 [3.6] | 23.4 [3.7] | 0.515* | 0.003 |
BMI: body mass index, SD: standerd deviation, *: student’s t-test, †: Chi-square test, ASD: Absolute standerdized difference
Outcomes before Propensity-score Matched Analysis.
| GIE group | X-ray group | p | |
|---|---|---|---|
| Hp infection, postive | 5,056 | - | |
| post eradication | 1,788 | - | |
| negative | 2,298 | - | |
| Detection rate of all U-GI malignancies, n (%) | 44 (0.48) | 3 (0.08) | 0.005* |
| Positive predictive value (95%CI) (%) | 3.48 (2.60-4.63) | 0.73 (0.25-2.13) | 0.003* |
| Detection rate of gastric cancer, n (%) | 34 (0.37) | 3 (0.08) | 0.003* |
| Stage I/II/III/IV | 32/2/0/0 | 2/1/0/0 | |
| Treatment method (endoscopic/surgical) | 31/3 | 1/2 | |
| Clinical outcome (curative/non-curative) | 33/1 | 3/0 | |
| Detection rate of other U-GI malignancies, n (%) | 10 (0.11) | 0 (0.00) | 0.036* |
| Hypopharyngeal cancer | 2 | 0 | |
| Esophageal cancer | 5 | 0 | |
| Duodenal cancer | 2 | 0 | |
| Duodenal GIST | 1 | 0 | |
| Treatment method (endoscopic/surgical/radiation) | 5/3/1 | 0 | |
| Clinical outcome (curative/non-curative) | 10/0 | 0 | |
| Adverse events | 6 (0.07) | 18 (0.45) | <0.0001* |
Hp: Helicobacter pylori, U-GI: upper-gastrointestinal, SMT: submucosal tumor, *: student's t-test
Outcomes after Propensity-score Matched Analysis.
| GIE group | X-ray group | p | |
|---|---|---|---|
| Detection rate of all U-GI malignancies, n (%) | 19 (1.23%) | 3 (0.19%) | 0.001* |
| Detection rate of gastric cancer, n (%) | 16 (1.03%) | 3 (0.19%) | 0.003* |
| Detection rate of other U-GI malignancies, n (%) | 3 (0.19%) | 0 (0.00%) | 0.005* |
U-GI: upper-gastrointestinal, *: student's t-test